Added to YB: 2026-09-21
Pitch date: 2026-09-16
MGNX [neutral]
MacroGenics, Inc.
-0.24%
current return
Author Info
No bio for this author
Company Info
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Market Cap
$263.7M
Pitch Price
$4.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.84
P/E
-2.59
EV/Sales
0.72
Sector
Biotechnology
Category
special_situation
Biotech Conferences Week 2 Day 3 Part 1 - MacroGenics, Inc.
MGNX (quick overview): MacroGenics is a restructured oncology-antibody company and credible target or partner candidate, with approximately $327M of pro forma cash and runway through the end of 2028 providing flexibility to develop and partner its focused pipeline. The thesis hinges on late-October ESMO data showing that lead B7-H3 ADC MGC026 can deliver competitive responses, durability and safety in head-and-neck squamous-cell carcinoma—particularly continued absence of ILD—against well-financed competitors.
Read full article (2 min)